Deutsche Bank
ZNTL icon

Deutsche Bank’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Deutsche Bank’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-42,804
Closed -$68.1K – 3758
2025
Q1 		$68.1K Hold
42,804
– – ﹤0.01% 3313
2024
Q4 		$130K Buy
42,804
+10,873
+34% +$35.6K ﹤0.01% 3223
2024
Q3 		$118K Buy
31,931
+8,184
+34% +$29.7K ﹤0.01% 3159
2024
Q2 		$97.1K Sell
23,747
-7,078
-23% -$79K ﹤0.01% 3118
2024
Q1 		$486K Sell
30,825
-12,081
-28% -$166K ﹤0.01% 2365
2023
Q4 		$650K Buy
42,906
+10,826
+34% +$158K ﹤0.01% 2240
2023
Q3 		$644K Sell
32,080
-387,146
-92% -$9.83M ﹤0.01% 2002
2023
Q2 		$11.8M Buy
419,226
+374,402
+835% +$8.98M 0.01% 927
2023
Q1 		$771K Buy
44,824
+7,428
+20% +$150K ﹤0.01% 2255
2022
Q4 		$753K Sell
37,396
-31,258
-46% -$672K ﹤0.01% 2225
2022
Q3 		$1.49M Buy
68,654
+46,126
+205% +$1.26M ﹤0.01% 1748
2022
Q2 		$633K Sell
22,528
-10,624
-32% -$281K ﹤0.01% 2452
2022
Q1 		$1.53M Sell
33,152
-1,834
-5% -$98.9K ﹤0.01% 2054
2021
Q4 		$2.94M Buy
34,986
+1,183
+3% +$91.5K ﹤0.01% 1756
2021
Q3 		$2.25M Buy
33,803
+11,438
+51% +$660K ﹤0.01% 2006
2021
Q2 		$1.19M Buy
22,365
+831
+4% +$44.5K ﹤0.01% 2666
2021
Q1 		$934K Sell
21,534
-1,843
-8% -$79.3K ﹤0.01% 2709
2020
Q4 		$1.21M Buy
23,377
+17,122
+274% +$772K ﹤0.01% 2316
2020
Q3 		$205K Buy
6,255
+1,019
+19% +$35.7K ﹤0.01% 3201
2020
Q2 		$252K Buy
+5,236
New +$201K ﹤0.01% 3026

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Deutsche Bank's ZNTL Position: Q2 2025 in Review

Deutsche Bank sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 42,804 shares — an estimated $68.1K sold.

Deutsche Bank first reported a position in ZNTL in Q2 2020 and held it in 20 quarters. The position peaked at $11.8M in Q2 2023. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • Deutsche Bank reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Deutsche Bank sold 42,804 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $68.1K.
  • Deutsche Bank first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 20 quarters.
  • Deutsche Bank's Zentalis Pharmaceuticals position peaked at $11.8M in Q2 2023.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on Deutsche Bank's 13F filing for Q2 2025, filed 12 Aug 2025.